Mesoblast (NASDAQ:MESO) Shares Gap Up – Here’s What Happened

by · The Cerbat Gem

Mesoblast Limited (NASDAQ:MESO – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $14.63, but opened at $15.72. Mesoblast shares last traded at $15.86, with a volume of 218,619 shares.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MESO. Piper Sandler lifted their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday. StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Tuesday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. Finally, Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.50.

Check Out Our Latest Analysis on MESO

Mesoblast Trading Up 10.3 %

The company has a 50 day moving average price of $10.48 and a 200 day moving average price of $8.29. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Hedge Funds Weigh In On Mesoblast

Several institutional investors have recently modified their holdings of the business. Signaturefd LLC raised its stake in Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after buying an additional 3,099 shares in the last quarter. Pine Valley Investments Ltd Liability Co purchased a new position in Mesoblast in the second quarter valued at approximately $80,000. Perkins Coie Trust Co raised its holdings in Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after purchasing an additional 1,500 shares in the last quarter. Rathbones Group PLC purchased a new stake in shares of Mesoblast during the 2nd quarter worth approximately $95,000. Finally, XTX Topco Ltd acquired a new position in shares of Mesoblast in the 2nd quarter valued at $103,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

(Get Free Report)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Further Reading